Healthcare & Life Sciences
Gene Editing & Longevity Biotech
Gene editing and longevity biotech reached a landmark inflection point in 2026: Intellia Therapeutics' in vivo CRISPR therapy lonvo-z succeeded in a Phase 3 trial for hereditary angioedema (an 87% reduction in attack rate) and began a rolling FDA submission that could make it the first approved in vivo gene-editing therapy for any disease, validating over a decade of CRISPR therapeutic development. In parallel, longevity biotech attracted massive capital inflows led by Altos Labs (more than $3 billion raised, backed by Jeff Bezos and Yuri Milner, now approaching clinical trials on cellular reprogramming) and Retro Biosciences (backed by OpenAI's Sam Altman, reaching a $1.8 billion valuation while running its first clinical trial for an Alzheimer's protein-clearance therapy), reflecting a broader shift of both venture capital and tech-industry wealth into genetic medicine and aging research as distinct, non-AI-native biotechnology categories.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source · 52% avg. source confidence
- Nature Biotechnology / CNBC — Intellia's CRISPR therapy achieves landmark Phase 3 success52% source confidence
Dependency Map
What Gene Editing & Longevity Biotech depends on below, and who depends on Gene Editing & Longevity Biotech above — click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Gene Editing & Longevity Biotech's Timeline
A sourced, dated history of Gene Editing & Longevity Biotech's key moments — founding to present.
Apr 2026 · Intellia's lonvo-z becomes first in vivo CRISPR therapy to succeed in Phase 3
Intellia Therapeutics' lonvo-z became the first in vivo CRISPR gene-editing therapy to succeed in a Phase 3 trial, reducing hereditary angioedema attack rates by 87% versus placebo and beginning a rolling FDA submission that could make it the first approved in vivo gene-editing therapy for any disease.